Wells Fargo & Company Cogent Biosciences, Inc. Transaction History
Wells Fargo & Company
- $410 Billion
- Q1 2024
A detailed history of Wells Fargo & Company transactions in Cogent Biosciences, Inc. stock. As of the latest transaction made, Wells Fargo & Company holds 26,853 shares of COGT stock, worth $252,149. This represents 0.0% of its overall portfolio holdings.
Number of Shares
26,853
Previous 23,723
13.19%
Holding current value
$252,149
Previous $139,000
29.5%
% of portfolio
0.0%
Previous 0.0%
Shares
13 transactions
Others Institutions Holding COGT
# of Institutions
160Shares Held
102MCall Options Held
197KPut Options Held
102K-
Kynam Capital Management, LP Princeton, NJ8.5MShares$79.8 Million5.99% of portfolio
-
State Street Corp Boston, MA7.63MShares$71.6 Million0.0% of portfolio
-
Black Rock Inc. New York, NY6.69MShares$62.8 Million0.0% of portfolio
-
Steven Cohen Point72 Asset Management, L.P. | Stamford, Ct6.68MShares$62.7 Million0.11% of portfolio
-
Commodore Capital LP New York, NY6.43MShares$60.3 Million3.73% of portfolio
About Cogent Biosciences, Inc.
- Ticker COGT
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 65,758,300
- Market Cap $617M
- Description
- Cogent Biosciences, Inc., a biotechnology company, focuses on developing precision therapies for genetically defined diseases. Its lead product candidate includes CGT9486, a selective tyrosine kinase inhibitor designed to inhibit the KIT D816V mutation that drives systemic mastocytosis, as well as other mutations in KIT exon 17, which are found ...